Hadean, a UK-based company, has developed a cloud-native supercomputing platform. Their Hadean Platform, a distributed computing platform, streamlines running applications via cloud by removing excessive middleware and helping scale the process – a journey that has taken them from the world of gaming to the modeling a pandemic.

Gilead Sciences continues to deepen its oncology pipeline, acquiring a 49.9 percent equity interest in Pionyr Immunotherapeutics for $275 million and an exclusive option to buy the rest of the company.

Sana Biotechnology, which launched during 2019, raised $700 million in initial financing that will be used to advance the company’s discovery and development programs that create and deliver engineered cells as a treatment for different disease types.

U.K.-based Bit Bio, a spinout of Cambridge University and previously known as Elpis Biotechnology, secured $41.5 million in a Series A funding round that will be used to support the company’s goal to transition biology into engineering.

Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer.

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

U.S. drugmaker Merck & Co. Inc. agreed to buy Peloton Therapeutics Inc. for $1.05 billion in cash, gaining access to the privately held company’s lead kidney cancer drug candidate.

With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.

The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”

Emeryville, Calif.-based Berkeley Lights closed on a $95 million financing round, led by Nikon.